H. Moebius

发表

Is it time to revise the diagnostic criteria for apathy in brain disorders? The 2018 international consensus group

J. Yesavage, K. Dujardin, V. Manera, 2018, European Psychiatry.

Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia

Thomas C. Baddeley, S. Gauthier, R. Staff, 2020, Journal of Alzheimer's disease : JAD.

A randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of neramexane in patients with moderate to severe subjective tinnitus

P. Jastreboff, H. Moebius, R. Görtelmeyer, 2011, BMC ear, nose, and throat disorders.

Effect of the Histone Deacetylase Inhibitor FRM-0334 on Progranulin Levels in Patients With Progranulin Gene Haploinsufficiency

G. Frisoni, B. Boeve, F. Pasquier, 2021, JAMA network open.

Predictive Power of Cognitive Biomarkers in Neurodegenerative Disease Drug Development: Utility of the P300 Event-Related Potential

J. Olichney, J. Xia, H. Moebius, 2022, Neural plasticity.

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial

Luc Bracoud, Roger T Staff, Charles S Davis, 2016, The Lancet.

Diagnostic criteria for apathy in neurocognitive disorders

David S. Miller, Corinne E. Fischer, V. Manera, 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

Phase II Trial of the Sigma-1 Receptor Agonist Cutamesine (SA4503) for Recovery Enhancement After Acute Ischemic Stroke

K. Muir, H. Moebius, E. Santamarina, 2014, Stroke.

Fosgonimeton, a Novel Positive Modulator of the HGF/MET System, Promotes Neurotrophic and Procognitive Effects in Models of Dementia

Wei Wu, H. Moebius, Andrée-Anne Berthiaume, 2022, Neurotherapeutics.

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer’s Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial

S. Hendrix, G. Viardot, H. Moebius, 2022, Journal of Alzheimer's disease : JAD.

Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial

Giovanni B. Frisoni, John Seibyl, Roger T. Staff, 2017, Journal of Alzheimer's disease : JAD.

Phase II Trial of the Sigma-1 Receptor Agonist Cutamesine ( SA 4503 ) for Recovery Enhancement After Acute Ischemic Stroke

K. Muir, H. Moebius, E. Santamarina, 2014 .

The Case for a Novel Therapeutic Approach to Dementia: Small Molecule Hepatocyte Growth Factor (HGF/MET) Positive Modulators

H. Moebius, Kevin J Church, Kevin J. Church, 2023, Journal of Alzheimer's disease : JAD.

No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use.

W. Danysz, G. Wenk, G. Quack, 2000, Life sciences.

EVP-6124, a selective alpha-7 partial agonist, has positive effects on cognition and clinical function in mild-to-moderate Alzheimer's disease patients: Results of a six-month, double-blind, placebo controlled, dose ranging study

D. Hilt, H. Moebius, G. Koenig, 2012, Alzheimer's & Dementia.

Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia

D. Hilt, R. Keefe, I. Lombardo, 2015, Neuropsychopharmacology.

A Framework for Developing Pharmacotherapy for Agitation in Alzheimer’s disease: Recommendations of the ISCTM Working Group

L. Ereshefsky, R. Khoury, T. Shiovitz, 2020, The Journal of Prevention of Alzheimer's Disease.

Memantine in moderately severe to severe Alzheimer's disease (AD): Results of a placebo-controlled 6-month trial

B. Reisberg, S. Ferris, H. Moebius, 2000, Neurobiology of Aging.

P.4.006 Long-term efficacy and safety benefits from treatment with the NMDA antagonist memantine: results of a 24-week, open-label extension study in moderate to severe Alzheimer's disease

B. Reisberg, F. Schmitt, H. Moebius, 2003, European Neuropsychopharmacology.

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial

L. Schneider, G. Frisoni, H. Feldman, 2016, The Lancet.

PHASE 2A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE HISTONE DEACETYLASE INHIBITOR (HDACI), FRM-0334, IN ASYMPTOMATIC CARRIERS OF, OR PATIENTS WITH FRONTOTEMPORAL LOBAR DEGENERATION (FTLD) DUE TO, PROGRANULIN GENE MUTATIONS

G. Frisoni, B. Boeve, F. Pasquier, 2019, Alzheimer's & Dementia.